Spoken Alpha
CERS
CERUS CORP
Overview
CERUS CORP is a Healthcare company operating in Medical Devices with a $517.0M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-04-3011 Q&A exchanges
- Q4 FY2025Earnings2026-03-027 Q&A exchanges
- Q3 FY2025Earnings2025-11-064 Q&A exchanges
- Q2 FY2025Earnings2025-08-054 Q&A exchanges
- Q1 FY2025Earnings2025-05-0111 Q&A exchanges
- Q4 FY2024Earnings2025-02-2017 Q&A exchanges
- Q3 FY2024Earnings2024-10-3014 Q&A exchanges
- Q2 FY2024Earnings2024-08-0115 Q&A exchanges
- Q1 FY2024Earnings2024-05-0215 Q&A exchanges
- Q4 FY2023Earnings2024-03-0510 Q&A exchanges
- Q3 FY2023Earnings2023-11-026 Q&A exchanges
- Q2 FY2023Earnings2023-08-0214 Q&A exchanges
- Q1 FY2023Earnings2023-05-048 Q&A exchanges
- Q4 FY2022Earnings2023-02-289 Q&A exchanges
- Q3 FY2022Earnings2022-11-035 Q&A exchanges
- Q2 FY2022Earnings2022-08-0415 Q&A exchanges
- Q1 FY2022Earnings2022-05-0510 Q&A exchanges
- Q4 FY2021Earnings2022-02-227 Q&A exchanges
- Q3 FY2021Earnings2021-11-0216 Q&A exchanges
- Q2 FY2021Earnings2021-08-0317 Q&A exchanges
- Q1 FY2021Earnings2021-05-0510 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-03EPS— vs $-0.01—Rev— vs ——EODHD
- Q1 FY20262026-04-29EPS$-0.01 vs $-0.03+66.7%Rev$59.9M vs ——EODHD
- Q4 FY20252026-02-18EPS$-0.01 vs $-0.01-33.3%Rev$57.8M vs ——EODHD
- Q3 FY20252025-11-05EPS$-0.00 vs $-0.03+99.7%Rev$52.7M vs ——EODHD
- Q2 FY20252025-07-29EPS$-0.03 vs $-0.02-33.3%Rev$52.4M vs ——EODHD
- Q1 FY20252025-04-29EPS$-0.04 vs $-0.05+20.0%Rev$43.2M vs ——EODHD
- Q4 FY20242025-03-02EPS$-0.01 vs $-0.010.0%Rev$50.8M vs ——EODHD
- Q3 FY20242024-10-29EPS$-0.02 vs $-0.03+33.3%Rev$46.0M vs ——EODHD
- Q2 FY20242024-07-31EPS$-0.03 vs $-0.04+25.0%Rev$45.1M vs ——EODHD
- Q1 FY20242024-05-01EPS$-0.05 vs $-0.050.0%Rev$38.4M vs ——EODHD
- Q4 FY20232024-03-04EPS$-0.01 vs $-0.02+50.0%Rev$46.8M vs ——EODHD
- Q3 FY20232023-11-01EPS$-0.03 vs $-0.05+40.0%Rev$39.8M vs ——EODHD
- Q2 FY20232023-08-01EPS$-0.06 vs $-0.060.0%Rev$38.9M vs ——EODHD
- Q1 FY20232023-05-03EPS$-0.09 vs $-0.07-28.6%Rev$31.0M vs ——EODHD
- Q4 FY20222023-02-27EPS$-0.08 vs $-0.05-60.0%Rev$44.0M vs ——EODHD
- Q3 FY20222022-11-02EPS$-0.05 vs $-0.06+16.7%Rev$39.6M vs ——EODHD
- Q2 FY20222022-08-03EPS$-0.05 vs $-0.07+28.6%Rev$41.0M vs ——EODHD
- Q1 FY20222022-05-04EPS$-0.07 vs $-0.09+22.2%Rev$37.4M vs ——EODHD
- Q4 FY20212022-02-21EPS$-0.05 vs $-0.08+37.5%Rev$39.9M vs ——EODHD
- Q3 FY20212021-11-01EPS$-0.07 vs $-0.09+22.2%Rev$36.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-03 | — | $-0.01 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-04-29 | $-0.01 | $-0.03 | +66.7% | $59.9M | — | — | EODHD |
| Q4 FY2025 | 2026-02-18 | $-0.01 | $-0.01 | -33.3% | $57.8M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-0.00 | $-0.03 | +99.7% | $52.7M | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $-0.03 | $-0.02 | -33.3% | $52.4M | — | — | EODHD |
| Q1 FY2025 | 2025-04-29 | $-0.04 | $-0.05 | +20.0% | $43.2M | — | — | EODHD |
| Q4 FY2024 | 2025-03-02 | $-0.01 | $-0.01 | 0.0% | $50.8M | — | — | EODHD |
| Q3 FY2024 | 2024-10-29 | $-0.02 | $-0.03 | +33.3% | $46.0M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.03 | $-0.04 | +25.0% | $45.1M | — | — | EODHD |
| Q1 FY2024 | 2024-05-01 | $-0.05 | $-0.05 | 0.0% | $38.4M | — | — | EODHD |
| Q4 FY2023 | 2024-03-04 | $-0.01 | $-0.02 | +50.0% | $46.8M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-0.03 | $-0.05 | +40.0% | $39.8M | — | — | EODHD |
| Q2 FY2023 | 2023-08-01 | $-0.06 | $-0.06 | 0.0% | $38.9M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.09 | $-0.07 | -28.6% | $31.0M | — | — | EODHD |
| Q4 FY2022 | 2023-02-27 | $-0.08 | $-0.05 | -60.0% | $44.0M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.05 | $-0.06 | +16.7% | $39.6M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-0.05 | $-0.07 | +28.6% | $41.0M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-0.07 | $-0.09 | +22.2% | $37.4M | — | — | EODHD |
| Q4 FY2021 | 2022-02-21 | $-0.05 | $-0.08 | +37.5% | $39.9M | — | — | EODHD |
| Q3 FY2021 | 2021-11-01 | $-0.07 | $-0.09 | +22.2% | $36.1M | — | — | EODHD |
Source: EODHD. CERS reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks CERS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 9/10 quarters with 80% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.96 | $4.56 | +8.7% | -1.8% | -3.0% |
| Q4 FY2026 | $4.76 | $4.49 | +6.0% | -1.1% | -2.6% |
| Q3 FY2026 | $4.38 | $4.38 | 0.0% | +0.5% | +1.2% |
| Q2 FY2026 | $5.16 | $4.61 | +11.9% | +4.9% | +7.6% |
| Q1 FY2025 | $4.38 | $4.42 | -1.0% | +0.4% | -1.4% |
| Q4 FY2025 | $5.23 | $4.70 | +11.3% | +7.3% | +4.8% |
| Q3 FY2025 | $4.65 | $4.59 | +1.4% | +2.2% | +1.8% |
| Q2 FY2025 | $4.87 | $4.62 | +5.5% | +1.2% | +0.2% |
| Q1 FY2024 | $4.77 | $4.61 | +3.4% | +3.2% | +5.6% |
| Q4 FY2024 | $4.87 | $4.77 | +2.1% | +1.5% | +4.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Maintained2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Maintained2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Maintained2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- William Mariner GreenmanCEO1 yr 3 mono recorded callsCurrentSample
CEO since 2025 • 1/4 beats (25%) • last guidance cut Q3 FY2026
- Kevin Dennis GreenCFO1 yr 3 mono recorded callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last call held guidance Q1 FY2026
- Vivek K JayaramanCOO1 yr 3 mo20 callsCurrentSample
COO since 2025 • 2/4 beats (50%) • last guidance raise Q2 FY2026
- Richard J BenjaminChief Medical Officer1 yr 3 mo1 callCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance cut Q3 FY2026
- Chrystal JensenChief Legal Officer1 yr 3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance raise Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CERS.
$ curl https://api.spokenalpha.com/v1/companies/CERSFAQ
Frequently asked about CERS
Where can I find CERUS CORP's (CERS) earnings call transcripts?
Spoken Alpha indexes CERS's earnings call transcripts at https://spokenalpha.com/companies/CERS. Each call links to attributed speakers and parsed analyst Q&A. CERUS CORP's own investor relations page is at https://ir.cerus.com/home/default.aspx.
When was CERUS CORP's most recent earnings call?
CERUS CORP (CERS) held its most recent earnings call on 2026-04-30, covering fiscal Q1 2026.
What sector is CERS in?
CERUS CORP (CERS) operates in the Healthcare sector (Medical Devices industry).